Related Experiment Video
Updated: May 29, 2026
Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
Published on: September 27, 2024
Nanoparticle-based cerebral drug-delivery systems and antiangiogenic approach in gliomas treatment
Giuseppe Raudino1, Mariella Caffo, Gerardo Caruso
1Neurosurgical Clinic, Department of Neurosciences, Psychiatry and Anesthesiology, A.O.U. Policlinico G. Martino, via Consolare Valeria, 1, 98125 Messina, Italy.
Abstract:
The efficacy of current anti-cancer multimodal therapeutic strategies in gliomas is limited by the lack of specific therapies against malignant cells and the prognosis in patients affected by cerebral gliomas remains very unfavorable. Glial tumors seem to be able to create a favorable environment for the invasion of neoplastic cells when they combine with the extracellular matrix through the up-regulation of crucial pathways such as angiogenesis and invasion. The major problem in brain drug delivery is the presence of the blood brain barrier which limits the delivery of many chemotherapeutic agents and other kinds of therapeutic molecules. This event often contributes to the failure of the treatment. Nanoparticle systems can represent ideal devices for delivery of specific compounds to brain tumors across the blood brain barrier. The specificity of hybridization makes antisense method an interesting strategy to selectively modulate the expression of genes involved in tumorigenesis. In this review we will focus on the mechanisms of angiogenesis into gliomas, their importance into tumor progression and the possibilities to block these mechanisms with new nanoparticle-based therapeutic strategies. We will also report the results of preclinical and/or clinical studies that adopt nanoparticle-based antiangiogenic therapeutic approach in cerebral gliomas, considering also some patents deal with antiangiogenic strategy.
Insights
New nanoparticle strategies show promise for treating brain gliomas by targeting angiogenesis and overcoming the blood-brain barrier. This approach aims to improve therapeutic efficacy for these aggressive tumors.
Area of Science:
- Oncology
- Nanotechnology
- Neuroscience
Background:
- Glioma treatment efficacy is limited by non-specific therapies and poor prognosis.
- Tumor progression involves angiogenesis and invasion, facilitated by the extracellular matrix.
- The blood-brain barrier restricts the delivery of effective chemotherapeutics to brain tumors.
Purpose of the Study:
- To review glioma angiogenesis mechanisms and their role in tumor progression.
- To explore nanoparticle-based strategies for blocking glioma angiogenesis.
- To discuss preclinical and clinical studies on nanoparticle anti-angiogenic therapy for gliomas.
Main Methods:
- Review of literature on glioma angiogenesis and nanoparticle drug delivery.
- Analysis of antisense technology for gene expression modulation in tumorigenesis.
- Examination of preclinical and clinical studies and patents related to anti-angiogenic nanoparticle strategies.
Main Results:
- Nanoparticle systems offer potential for targeted drug delivery across the blood-brain barrier.
- Antisense methods provide specificity for modulating genes involved in glioma development.
- Preclinical and clinical data suggest efficacy of nanoparticle-based anti-angiogenic approaches.
Conclusions:
- Nanoparticle-based anti-angiogenic therapies represent a promising strategy for cerebral gliomas.
- Targeting angiogenesis and utilizing the blood-brain barrier penetration of nanoparticles can improve treatment outcomes.
- Further research and clinical translation of these strategies are warranted.
